FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-06-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post Marketing Surveillance Study on Emselex After Launch in Germany

NCT00786448

Overactive Bladder

COMPLETED

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

NCT00171184

Overactive Bladder

COMPLETED PHASE4

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

NCT00366002

Overactive Bladder (OAB)

COMPLETED PHASE4

A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder

NCT00170755

Overactive Bladder Syndrome

COMPLETED PHASE3

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

NCT00629642

Multiple Sclerosis Neurogenic Bladder Spinal Cord Diseases

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Darifenacin (Emselex, BAY79-4998)

Intervention Type DRUG

Patients in daily clinical treatment receiving Emselex according to local drug information

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darifenacin (Emselex, BAY79-4998)

Patients in daily clinical treatment receiving Emselex according to local drug information

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients \> 18 years with symptoms of overactive bladder.

Exclusion Criteria

* Contraindications for the treatment with Darifenacin prolonged-release tablets according to the registered package insert.
* Pregnancy and lactation. Women of childbearing potential have to use an acceptable method of contraception.
* Concomitant treatment with drugs known to affect mainly the urinary bladder function (e.g. anticholinergics, antispasmodics) at any time during the study. Concomitant treatment with botulinum toxin, capsaicin or resiniferatoxin at any time during the study and treatment with botulinum toxin, capsaicin or resiniferatoxin in the last 6 months prior to Visit 1.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No